Merck insomnia drug reports positive Phase IIb data at SLEEP meeting
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck's investigational dual orexin receptor antagonist (DORA) was significantly better than placebo at improving overall sleep at one night and at the end of week four in patients with primary insomnia in a Phase IIb study, the company reported at the annual Meeting of the Associated Professional Sleep Societies in San Antonio June 9. Orexin antagonists are thought to block the stimulation of the brain's arousal system in the hypothalamus. In the dose-ranging study, 243 patients were randomized to one of four doses of MK-4305 and 249 to placebo. The co-primary endpoint was improvement in sleep efficiency on night one and at the end of four weeks. Secondary endpoints were improvement in wake after sleep onset and latency to persistent sleep, compared to placebo. Phase III trials examining MK-4305 in elderly and non-elderly insomnia populations are ongoing, and Merck is targeting 2012 for a filing
You may also be interested in...
New China COVID Vaccine Arriving But COVAX Pledge May Need A Booster
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.
QUOTED. 9 March 2021. Matthew Trerotola.
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: